GLP Medications Cut 12-Month Mortality Risk by 29% in Type 2 Diabetes Patients Post-COVID-19
Background
Individuals with Type 2 Diabetes Mellitus (T2DM) face heightened risks for severe outcomes from COVID-19, including increased mortality and prolonged complications like Long COVID. Current standard-of-care for T2DM primarily focuses on glycemic control, but the broader systemic inflammation and cardiovascular stress induced by COVID-19 necessitate therapies with pleiotropic protective effects. Glucagon-like peptide-1 receptor agonist (GLP) medications, known for their antihyperglycemic, weight loss, anti-inflammatory, and cardiovascular benefits, represent a promising class to mitigate these severe post-COVID-19 consequences.
Study Design
Researchers conducted a retrospective cohort study using electronic health record data from the National Clinical Cohort Collaborative. They included 14,215 individuals with type 2 diabetes mellitus and COVID-19 who were prescribed either a GLP medication (treatment group) or a sodium-glucose co-transporter 2 inhibitor (SGLT2i) (comparator group). Participants developed acute COVID-19 between October 1, 2021, and April 1, 2023. The primary endpoints were the 12-month cumulative incidence of mortality and Long COVID (diagnosed or probable via computational phenotype). Statistical analysis used targeted maximum likelihood estimation to compare outcome risks, adjusting for covariates.
Results
Among 14,215 individuals (mean age 60 years; mean BMI 37) with COVID-19 and type 2 diabetes, GLP medication prescription was significantly associated with a lower risk of mortality compared to SGLT2i. The adjusted risk ratio (aRR) for mortality was 0.71 (95% CI 0.53, 0.95), indicating a 29% reduction in mortality risk. This suggests a substantial protective effect against severe outcomes. However, GLP medication prescription did not show a significant association with a lower risk of Long COVID diagnosis (aRR 1.01; 95% CI 0.80, 1.27) or probable Long COVID (aRR 0.94; 95% CI 0.88, 1.01).
Key Findings
- GLP medication prescription was associated with a lower 12-month mortality risk post-COVID-19.
- Mortality risk was reduced by 29% (aRR 0.71; 95% CI 0.53, 0.95) in the GLP group vs. SGLT2i.
- No significant association was found between GLP medications and Long COVID diagnosis (aRR 1.01).
- No significant association was found between GLP medications and probable Long COVID (aRR 0.94).
- Study included 14,215 individuals with type 2 diabetes and COVID-19.
Why It Matters
This study suggests that GLP medications may offer a significant survival advantage for individuals with type 2 diabetes who contract COVID-19. For clinicians managing T2DM patients, especially those with a history of COVID-19, this finding reinforces the broader benefits of GLP-1RAs beyond glycemic control. While GLP medications did not impact Long COVID incidence in this cohort, their mortality benefit is a crucial consideration. This could influence prescribing decisions, potentially favoring GLP-1RAs in T2DM patients at high risk for severe post-COVID outcomes, integrating a new layer of protective strategy into existing treatment protocols.
glp-1-agonist
type-2-diabetes
covid-19
mortality
sglt2i
retrospective-cohort